Trials / Terminated
TerminatedNCT01228019
Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)
Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of TREDAPTIVE Tablet in Usual Practice
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,166 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This survey is being conducted to assess the safety and efficacy of niacin (+) laropiprant (TREDAPTIVE) in usual practice in Korea according to the new product re-examination regulations of the Korean Food and Drug Administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niacin (+) laropiprant | Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2010-10-25
- Last updated
- 2015-04-21
- Results posted
- 2014-04-25
Source: ClinicalTrials.gov record NCT01228019. Inclusion in this directory is not an endorsement.